ClinicalTrials.gg
RecruitingNCT05583513Updated Nov 17, 2026

Heart Failure Evaluation Study

An observational study in Heart Failure, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Chinese University of Hong Kong · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Heart Failure by Chinese University of Hong Kong — 7 open to participants now, 7 under way, 1 of them phase 3. Heart Failure · Chinese University of Hong Kong.

Started
2022
with 2 others
Observational
7 of 15
4 open now
Registered
10th of 15
by date

Among the 15 studies in Heart Failure by Chinese University of Hong Kong, this one is one of 3 that started in 2022, is one of 7 observational ones, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 15 studies in Heart Failure by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Heart failure (HF) is a highly prevalent conditions that impose a significant burden to the patients, the hospital and the healthcare system. In Hong Kong, HF was one of the commonest causes of hospitalization and death. While HF with reduced ejection fraction (HFrEF) infer high mortality, HF with preserved ejection fraction (HFpEF) can be equally debilitating with similar hospital readmission rate and decline in functional status. Despite recent advancement and approval of novel pharmacologic agents and device therapies to treat HF, HF remains difficult to manage, with increased mortality and frequent hospitalization. HF is characterized by a gradual progression with intervals of exacerbation that often necessitating frequent re-admission. These readmissions are common with up to 1 quarter of patients readmitting within 30 days and half within 6 months8. An ambulatory HF centre can serve both as a transition of care from inpatients to community setting and as a point-of-care for early HF exacerbation (HFE) to prevent recurrent HF hospitalization. This is a registry study aims to investigate the progression disease and its impact on the quality of life (QoL) of the patients who are managed at the ambulatory HF clinic.

Read the detailed description

Patient population and study location All patients managed at the Prince of Wales Hospital Ambulatory Heart Failure clinic will be recruited into this registry. Patients' consent will be sought from either the patients or their legal guardian should the patients deemed incapable to consent. There are no exclusion criteria.

Collectable Data Patients' demographic information, clinical characteristic including co-morbidities and physical findings, medication records, laboratory parameter including basic blood test and cardiac enzymes which include NT-pro BNP level, imaging parameters including echocardiographic findings and other relevant cardiac imaging findings will be recorded at baseline and at every visit. Patients' functional class as measure by the New York Heart Association (NYHA) classification and their 6 minute walk test will be recorded at selected time point. Patient's Health-related Quality of Life will be measured using both the Minnesota Living with Heart Failure Questionaire (MLHFQ) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at selected time-point. The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL. The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL. All subjects will have the Chinese version of the questionnaire administered by research team at baseline, 3-month and 12-month.

Intervention Since this is a registry, no active intervention will be provided. Treatment of HF will be dictated by the responsible physician.

Duration This registry aim to follow patients for long term.

Analysis All statistical analysis will be performed using STATA version 15 software (College Station, TX, USA). Continuous variables were described by using descriptive statistics including means, medians, and SDs. Frequencies were used for categorical variables. The prevalence of use of each drug was expressed as the percentage of patients using the drug. Wilcoxon Signed Rank Test was performed to test for statistical significance of the differences in NYHA, KCCQ-12 and MLHFQ scores at 3-month and 12-month with respect to the baseline. Kaplan-Meier survival analysis will be performed for time to first hospital admission and death, with time censored at death or on last follow-date. The effect of clinical categories on time to first hospitalization was assessed using adjusted Cox proportional hazards models. Repeat hospitalization outcomes were examined using Cox regression analysis for recurrent events, accounting for the possibility of multiple readmissions occurring over time in the same patient. We treat death and hospitalization as separate competing events. The lifetime of the HF patient is defined to begin on the first registration to the clinic. The MLHFQ-21 and KCCQ-12 domain and summary scores were analysed as continuous variables and grouped scores categories for analysis.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart failure
  • HF with reduced ejection fraction
  • HF with preserved ejection fraction
  • HF exacerbation
  • quality of life
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population is base on the primary objective

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Subject age >18 receiving management at the Ambulatory Heart Failure Clinic

Exclusion criteria

Exclusion Criteria:

1. Subject is unable or unwilling to provide written consent prior to enrollment

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Ambulatory Heart Failure

    Diagnostic Test: MLHFQ (Minnesota Living with Heart Failure Questionnaire) · Diagnostic Test: KCCQ (the Kansas City Cardiomyopathy Questionnaire)

Interventions

  • Diagnostic testMLHFQ (Minnesota Living with Heart Failure Questionnaire)

    The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL

  • Diagnostic testKCCQ (the Kansas City Cardiomyopathy Questionnaire)

    The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL

06

What researchers measure

Primary outcomes

  1. Time to first rehospitalization

    Time frame: Change from time to first rehospitalization at 12-months

  2. 100 patient-year readmission rate

    Time frame: Change from 100 patient-year readmission rate at 12-months

  3. Change in functional class as measured by NYHA class over times

    Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. No NYHA class listed or unable to determine.

    Time frame: Change from functional class as measured by NYHA class over times at 12-months

  4. Change in QoL as measured by MLHFQ and KCCQ over times

    The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL. The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL.

    Time frame: Change from QoL as measured by MLHFQ over times at 12-months

  5. Change in QoL as measured by KCCQ over times

    The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL.

    Time frame: Change from QoL as measured by KCCQ over times at 12-months

  6. Heart-failure related mortality

    Time frame: Change from Heart-failure related mortality at 12-months

Secondary outcomes

  1. Change in number of Participants With Abnormal Laboratory Values

    Time frame: Change from number of Participants With Abnormal Laboratory Values at 12-months

  2. Change in patients' laboratory parameters

    Time frame: Change from patients' laboratory parameters at 12-months

  3. Change from baseline in log-transformed NT-proBNP level over time

    Time frame: Change from baseline in log-transformed NT-proBNP level over time at 12-months

  4. Change in 6MWT

    Time frame: Change from 6MWT at 12-months

  5. Change of cardiovascular medications

    Change of cardiovascular medications, including ACEI/ARB/ARNI, Beta-blockers, Calcium Channel Blockers, Diuretics, Aldosterone antagonist, antiplatelet, anticoagulation, anti-arrythmias, vasodilators, lipid-lowering agents, potassium supplements, SGLT2 inhibitors.

    Time frame: Change of cardiovascular medications at 12-months

  6. Cardiovascular and All-cause mortality

    Time frame: Change from cardiovascular and All-cause mortality at 12-months

  7. The costs of all services, medications and tests

    The costs of all services, medications and tests as estimated with reference to the Hong Kong Government Gazette 2020 and Hong Kong Hospital Authority Drug Formulary 2020

    Time frame: Change from costs of all services, medications and tests at 12-months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Arora S, Lahewala S, Hassan Virk HU, Setareh-Shenas S, Patel P, Kumar V, Tripathi B, Shah H, Patel V, Gidwani U, Deshmukh A, Badheka A, Gopalan R. Etiologies, Trends, and Predictors of 30-Day Readmissions in Patients With Diastolic Heart Failure. Am J Cardiol. 2017 Aug 15;120(4):616-624. doi: 10.1016/j.amjcard.2017.05.028. Epub 2017 Jun 1. PubMed 28648393 ↗
  • Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27. PubMed 33501848 ↗
  • Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2. PubMed 28785469 ↗
  • Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, Dunlay S, McNulty S, Chakraborty H, Stevenson LW, Redfield MM, Borlaug BA. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020 Jun;22(6):1009-1018. doi: 10.1002/ejhf.1788. Epub 2020 Mar 9. PubMed 32150314 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗
  • Writing Committee; Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 16;77(6):772-810. doi: 10.1016/j.jacc.2020.11.022. Epub 2021 Jan 11. No abstract available. PubMed 33446410 ↗
  • Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, Lee DS. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. 2012 Jul 1;5(4):414-21. doi: 10.1161/CIRCHEARTFAILURE.111.964791. Epub 2012 May 2. PubMed 22556322 ↗
  • Greene SJ, Mentz RJ, Felker GM. Outpatient Worsening Heart Failure as a Target for Therapy: A Review. JAMA Cardiol. 2018 Mar 1;3(3):252-259. doi: 10.1001/jamacardio.2017.5250. PubMed 29387880 ↗
  • DeVore AD, Allen LA, Eapen ZJ. Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. J Card Fail. 2015 Aug;21(8):667-73. doi: 10.1016/j.cardfail.2015.05.009. Epub 2015 May 22. PubMed 26009012 ↗
  • Zsilinszka R, Mentz RJ, DeVore AD, Eapen ZJ, Pang PS, Hernandez AF. Acute Heart Failure: Alternatives to Hospitalization. JACC Heart Fail. 2017 May;5(5):329-336. doi: 10.1016/j.jchf.2016.12.014. Epub 2017 Mar 8. PubMed 28285117 ↗
  • Hung YT, Cheung NT, Ip S, Fung H. Epidemiology of heart failure in Hong Kong, 1997. Hong Kong Med J. 2000 Jun;6(2):159-62. PubMed 10895138 ↗
  • Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000 Apr;35(5):1245-55. doi: 10.1016/s0735-1097(00)00531-3. PubMed 10758967 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2030, 96 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 96 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2023 → Oct 2030 and completion Oct 2023 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Oct 17, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Oct 1, 2030was Oct 2023
CompletionEst.
Oct 1, 2030was Oct 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 17, 2026
Sites
Prince of Wales Hospital is now Recruiting
Nov 17, 2026
Primary completion
Oct 1, 2023→Oct 1, 2030
Nov 17, 2026
Study completion
Oct 1, 2023→Oct 1, 2030
Nov 17, 2026
Contact
Study contact now listed: added g•••@cuhk.edu.hk · •••9658; added x•••@gmail.com · •••1748. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Prince of Wales Hospital · Hong Kong, Hong KongContact added t•••@ha.org.hk · •••9658
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Completed→Recruiting
    Prince of Wales Hospital is now Recruiting
    Primary completion Oct 1, 2023→Oct 1, 2030
    Study completion Oct 1, 2023→Oct 1, 2030
    Contact Study contact now listed: added g•••@cuhk.edu.hk · •••9658; added x•••@gmail.com · •••1748. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Prince of Wales Hospital · Hong Kong, Hong KongContact added t•••@ha.org.hk · •••9658
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05583513
Responsible party
GuangMing Tan (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Oct 17, 2022
Start date
Oct 1, 2022
Primary completion
Oct 1, 2030 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

GuangMing Tan, MD
Contact
gtan@cuhk.edu.hk
85255699658
Daniel Xu
Contact
xjldaniel@gmail.com
852 7382 1748

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion